Details of Disease

General Information of Disease (ID: DISJAVM1)

• Disease Name: Ebola virus infection
• Synonyms: Ebolavirus infectious disease; Ebolavirus caused disease or disorder; Ebola fever; Ebola virus disease; Ebolavirus disease or disorder; Ebola; EHF
• Disease Class: 1D60: Filovirus disease
• Definition: A viral hemorrhagic fever that is caused by the Ebola virus, which is transmitted by contact with infected animals or humans; it is characterized by high fever, unexplained bleeding, and a high mortality rate.
• Disease Hierarchy:
  DISUO8BR: Filoviridae infectious disease
  DISQEBTU: Viral hemorrhagic fever
  DISEM33Q: Infectious disease
  DISJAVM1: Ebola virus infection
• ICD Code:
  ICD-11: ICD-11: 1D60.0
  Expand ICD-9: 001,002,003,004,005,006,007,008,009,010,011,012,013,014,015,016,017,018,019,020,021,022,023,024,025,026,027,028,029,030,031,032,033,034,035,036,037,038,039,040,041,042,043,044,045,046,047,048,049,050,051,052,053,054,055,056,057,058,059,060,061,062,063,064,065,066,067,068,069,070,071,072,073,074,075,076,077,078,079,080,081,082,083,084,085,086,087,088,089,090,091,092,093,094,095,096,097,098,099,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,065.8
• Disease Identifiers:
  MONDO ID: MONDO_0005737
  MESH ID: D019142
  UMLS CUI: C0282687
  MedGen ID: 129219
  Orphanet ID: 319218
  SNOMED CT ID: 37109004

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Ansuvimab	DMUMOEV	Approved	Antibody	[1]
Remdesivir	DMBFZ6L	Approved	Small molecular drug	[2]

This Disease is Treated as An Indication in 21 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Ebola virus vaccine	DMGP6I7	Phase 3	NA	[3]
MVA-BN	DMH1UQ3	Phase 3	NA	[4]
MVA-BN Filo	DMF0G7A	Phase 3	NA	[5]
V920	DMBLE71	Phase 3	NA	[3]
VAC52150	DMOIKZP	Phase 3	Vaccine	[6]
MAb114	DM948AP	Phase 2/3	Antibody	[7]
ZMapp	DMGXJ7B	Phase 2/3	NA	[7]
Ebola recombinant viral vector vaccine	DMWJOI1	Phase 2	NA	[3]
Anti-Ebola mAb	DMK6XV5	Phase 1/2	NA	[2]
AVI-6002	DMVUW8A	Phase 1	NA	[8]
AVI-7537	DMLI9U6	Phase 1	Antisense drug	[9]
Ebola vaccine	DM6UNNH	Phase 1	NA	[10]
Ebola virus vaccine + Matrix-M	DM3VYUZ	Phase 1	NA	[3]
Ebola/Marburg vaccine	DMCW5ST	Phase 1	NA	[11]
INO-4201	DM827ZQ	Phase 1	Vaccine	[12]
INO-4212	DMYW0SB	Phase 1	NA	[3]
Recombinant viral vector vaccine	DMUK0ZS	Phase 1	NA	[13]
TKM-Ebola	DMYDMJY	Phase 1	NA	[14]
VesiculoVax	DM2DOEM	Phase 1	NA	[3]
VRC-EBOADV018-00-VP	DMAGZVY	Phase 1	NA	[15]
VRC-EBODNA023-00-VP	DME71RG	Phase 1	NA	[16]

This Disease is Treated as An Indication in 8 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AdHu5-ZGP	DM87FTQ	Investigative	NA	[17]
DEF-201	DMO159H	Investigative	NA	[17]
EV-075	DMM7MH7	Investigative	NA	[17]
FGI-103-723	DMOE5J6	Investigative	NA	[17]
FiloVax	DMM2KW0	Investigative	NA	[17]
PAV-617	DM1FHKP	Investigative	NA	[17]
PAV-667	DMPYW95	Investigative	NA	[17]
ST-383	DM6XOP5	Investigative	NA	[17]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 9 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
BST2	TT90BJT	Limited	Biomarker	[18]
CD209	TTBXIM9	Limited	Genetic Variation	[19]
DDX58	TTVB0O3	Limited	Biomarker	[20]
EIF5A	TTIVCNR	Limited	Biomarker	[21]
NEDD4	TT1QU6G	Limited	Biomarker	[22]
PIKFYVE	TTA4M1N	Limited	Biomarker	[23]
SMYD3	TTKLJYX	Limited	Biomarker	[24]
TPCN2	TTHQJ2Y	Limited	Altered Expression	[25]
TSG101	TTHU7JA	Limited	Biomarker	[26]

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC25A19	DTT82QK	Limited	Biomarker	[27]

This Disease Is Related to 53 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ANO6	OTTA5KQJ	Limited	Biomarker	[28]
APEX2	OTJ22LIT	Limited	Biomarker	[29]
BAG3	OTVXYUDQ	Limited	Biomarker	[30]
CDSN	OTQW4HV6	Limited	Genetic Variation	[31]
CLEC10A	OTD8HQT6	Limited	Biomarker	[32]
CLEC4G	OTUGTR0H	Limited	Biomarker	[33]
DISP1	OTLDFZSY	Limited	Biomarker	[34]
ERVW-1	OTWV8DXJ	Limited	Biomarker	[35]
FUZ	OTC427QQ	Limited	Biomarker	[36]
GALNT1	OTO3RO36	Limited	Biomarker	[37]
GP2	OTB6TMGY	Limited	Biomarker	[38]
GP5	OT3WGPR3	Limited	Biomarker	[39]
GTPBP1	OTA9KV6C	Limited	Altered Expression	[40]
HM13	OTGEO1LP	Limited	Biomarker	[41]
IFI30	OT9DERT1	Limited	Biomarker	[42]
IFITM3	OT2QP8D3	Limited	Biomarker	[43]
IRF9	OTK4MYQJ	Limited	Biomarker	[44]
ITPA	OTQ47WVR	Limited	Biomarker	[45]
KPNA1	OTEMVAJ6	Limited	Biomarker	[46]
KPNA5	OTUOKF1A	Limited	Biomarker	[47]
LAMP3	OTN0XL3W	Limited	Biomarker	[48]
LNPK	OTOBNX6G	Limited	Biomarker	[49]
LSAMP	OTYXVQX2	Limited	Biomarker	[48]
MAVS	OTTQ0J64	Limited	Biomarker	[50]
MYOM2	OTD2UOXW	Limited	Biomarker	[51]
NPC1	OTRIPICX	Limited	Biomarker	[52]
NTPCR	OTTRT6Z9	Limited	Biomarker	[45]
NUSAP1	OT85HIJ5	Limited	Biomarker	[49]
PELI1	OTMLBCLC	Limited	Biomarker	[53]
PLAAT4	OTI66SAJ	Limited	Biomarker	[20]
PRDM6	OTKY12D9	Limited	Biomarker	[53]
PRKRA	OTUTVZZU	Limited	Biomarker	[54]
RAB11A	OTC4FW0J	Limited	Biomarker	[55]
RETREG1	OTYOSLZX	Limited	Biomarker	[56]
RILP	OTT6K1GE	Limited	Biomarker	[57]
RLN3	OTQSQMUQ	Limited	Biomarker	[58]
ROBO3	OTPVG40S	Limited	Biomarker	[20]
RUVBL1	OTWV19L7	Limited	Biomarker	[59]
RUVBL2	OTGWJ4T4	Limited	Biomarker	[59]
SEPTIN8	OTSZLI64	Limited	Genetic Variation	[60]
SH3BP5	OTOOEGUJ	Limited	Biomarker	[61]
SIGLEC1	OTNWSQA9	Limited	Altered Expression	[62]
STAU1	OTTR5311	Limited	Biomarker	[63]
TIMD4	OTGGC20G	Limited	Biomarker	[64]
TRIM6	OTBSMX0B	Limited	Biomarker	[65]
DPAGT1	OTYEJAGZ	moderate	Biomarker	[66]
GNPTAB	OT2Z03OB	moderate	Biomarker	[66]
SARS1	OTFKXQ1O	Strong	Biomarker	[67]
SARS2	OTU4T99W	Strong	Biomarker	[67]
ARHGEF5	OTUVGFT9	Definitive	Biomarker	[68]
HAVCR1	OT184CRZ	Definitive	Biomarker	[68]
RBBP6	OTTVG4HU	Definitive	Biomarker	[69]
TIMELESS	OTD8DCBJ	Definitive	Biomarker	[68]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] ClinicalTrials.gov (NCT01913353) A Non-inferiority Trial to Compare MVA-BN Smallpox Vaccine to ACAM2000. U.S. National Institutes of Health.
• [5] ClinicalTrials.gov (NCT02661464) Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo. U.S. National Institutes of Health.
• [6] ClinicalTrials.gov (NCT04228783) A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants. U.S. National Institutes of Health.
• [7] ClinicalTrials.gov (NCT03719586) Investigational Therapeutics for the Treatment of People With Ebola Virus Disease. U.S. National Institutes of Health.
• [8] ClinicalTrials.gov (NCT01353027) Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus. U.S. National Institutes of Health.
• [9] ClinicalTrials.gov (NCT01593072) A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers. U.S. National Institutes of Health.
• [10] Clinical pipeline report, company report or official report of Johnson & Johnson.
• [11] Clinical pipeline report, company report or official report of Crucell.
• [12] Clinical pipeline report, company report or official report of Inovio Pharmaceuticals.
• [13] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020010)
• [14] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035377)
• [15] ClinicalTrials.gov (NCT00374309) Experimental Vaccine for Prevention of Ebola Virus Infection. U.S. National Institutes of Health.
• [16] ClinicalTrials.gov (NCT00605514) Ebola and Marburg Virus Vaccines. U.S. National Institutes of Health.
• [17] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [18] Cooperation of the Ebola Virus Proteins VP40 and GP(1,2) with BST2 To Activate NF-B Independently of Virus-Like Particle Trapping.J Virol. 2017 Oct 27;91(22):e01308-17. doi: 10.1128/JVI.01308-17. Print 2017 Nov 15.
• [19] Unraveling Sugar Binding Modes to DC-SIGN by Employing Fluorinated Carbohydrates.Molecules. 2019 Jun 25;24(12):2337. doi: 10.3390/molecules24122337.
• [20] RIG-I Recognition of RNA Targets: The Influence of Terminal Base Pair Sequence and Overhangs on Affinity and Signaling.Cell Rep. 2019 Dec 17;29(12):3807-3815.e3. doi: 10.1016/j.celrep.2019.11.052.
• [21] Differential Mechanisms for the Involvement of Polyamines and Hypusinated eIF5A in Ebola Virus Gene Expression.J Virol. 2018 Sep 26;92(20):e01260-18. doi: 10.1128/JVI.01260-18. Print 2018 Oct 15.
• [22] Binding site plasticity in viral PPxY Late domain recognition by the third WW domain of human NEDD4.Sci Rep. 2019 Oct 21;9(1):15076. doi: 10.1038/s41598-019-50701-3.
• [23] Ebola virus requires phosphatidylinositol (3,5) bisphosphate production for efficient viral entry.Virology. 2018 Jan 1;513:17-28. doi: 10.1016/j.virol.2017.09.028. Epub 2017 Oct 12.
• [24] Host factor SMYD3 is recruited by Ebola virus nucleoprotein to facilitate viral mRNA transcription.Emerg Microbes Infect. 2019;8(1):1347-1360. doi: 10.1080/22221751.2019.1662736.
• [25] Mining of Ebola virus entry inhibitors identifies approved drugs as two-pore channel pore blockers.Biochim Biophys Acta Mol Cell Res. 2019 Jul;1866(7):1151-1161. doi: 10.1016/j.bbamcr.2018.10.022. Epub 2018 Nov 5.
• [26] ALIX Rescues Budding of a Double PTAP/PPEY L-Domain Deletion Mutant of Ebola VP40: A Role for ALIX in Ebola Virus Egress.J Infect Dis. 2015 Oct 1;212 Suppl 2(Suppl 2):S138-45. doi: 10.1093/infdis/jiu838. Epub 2015 Mar 18.
• [27] Ebola virus. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment.Science. 2015 Feb 27;347(6225):995-8. doi: 10.1126/science.1258758.
• [28] Role of Transmembrane Protein 16F in the Incorporation of Phosphatidylserine Into Budding Ebola Virus Virions.J Infect Dis. 2018 Nov 22;218(suppl_5):S335-S345. doi: 10.1093/infdis/jiy485.
• [29] Periplasmic Nanobody-APEX2 Fusions Enable Facile Visualization of Ebola, Marburg, and Mngl virus Nucleoproteins, Alluding to Similar Antigenic Landscapes among Marburgvirus and Dianlovirus.Viruses. 2019 Apr 20;11(4):364. doi: 10.3390/v11040364.
• [30] Chaperone-Mediated Autophagy Protein BAG3 Negatively Regulates Ebola and Marburg VP40-Mediated Egress.PLoS Pathog. 2017 Jan 11;13(1):e1006132. doi: 10.1371/journal.ppat.1006132. eCollection 2017 Jan.
• [31] Identification of H209 as Essential for pH 8-Triggered Receptor-Independent Syncytium Formation by S Protein of Mouse Hepatitis Virus A59.J Virol. 2018 May 14;92(11):e00209-18. doi: 10.1128/JVI.00209-18. Print 2018 Jun 1.
• [32] Involvement of viral envelope GP2 in Ebola virus entry into cells expressing the macrophage galactose-type C-type lectin.Biochem Biophys Res Commun. 2011 Apr 1;407(1):74-8. doi: 10.1016/j.bbrc.2011.02.110. Epub 2011 Mar 6.
• [33] The Myeloid LSECtin Is a DAP12-Coupled Receptor That Is Crucial for Inflammatory Response Induced by Ebola Virus Glycoprotein.PLoS Pathog. 2016 Mar 4;12(3):e1005487. doi: 10.1371/journal.ppat.1005487. eCollection 2016 Mar.
• [34] Rapid deployment of a mobile biosafety level-3 laboratory in Sierra Leone during the 2014 Ebola virus epidemic.PLoS Negl Trop Dis. 2017 May 15;11(5):e0005622. doi: 10.1371/journal.pntd.0005622. eCollection 2017 May.
• [35] Molecular modelling studies on adamantane-based Ebola virus GP-1 inhibitors using docking, pharmacophore and 3D-QSAR.SAR QSAR Environ Res. 2019 Mar;30(3):161-180. doi: 10.1080/1062936X.2019.1573377. Epub 2019 Feb 20.
• [36] Commentary: restarting NTD programme activities after the Ebola outbreak in Liberia.Infect Dis Poverty. 2017 May 1;6(1):52. doi: 10.1186/s40249-017-0272-8.
• [37] Site-specific glycosylation of Ebola virus glycoprotein by human polypeptide GalNAc-transferase 1 induces cell adhesion defects.J Biol Chem. 2018 Dec 21;293(51):19866-19873. doi: 10.1074/jbc.RA118.005375. Epub 2018 Nov 2.
• [38] Identification of Ebola Virus Inhibitors Targeting GP2 Using Principles of Molecular Mimicry.J Virol. 2019 Jul 17;93(15):e00676-19. doi: 10.1128/JVI.00676-19. Print 2019 Aug 1.
• [39] Characterization of the inhibitory effect of an extract of Prunella vulgaris on Ebola virus glycoprotein (GP)-mediated virus entry and infection.Antiviral Res. 2016 Mar;127:20-31. doi: 10.1016/j.antiviral.2016.01.001. Epub 2016 Jan 9.
• [40] Overexpression of Ebola virus envelope GP1 protein.Protein Expr Purif. 2017 Jul;135:45-53. doi: 10.1016/j.pep.2017.04.010. Epub 2017 Apr 27.
• [41] Inhibitors of signal peptide peptidase and subtilisin/kexin-isozyme 1 inhibit Ebola virus glycoprotein-driven cell entry by interfering with activity and cellular localization of endosomal cathepsins.PLoS One. 2019 Apr 11;14(4):e0214968. doi: 10.1371/journal.pone.0214968. eCollection 2019.
• [42] GILT restricts the cellular entry mediated by the envelope glycoproteins of SARS-CoV, Ebola virus and Lassa fever virus.Emerg Microbes Infect. 2019;8(1):1511-1523. doi: 10.1080/22221751.2019.1677446.
• [43] Chemical Synthesis of the Highly Hydrophobic Antiviral Membrane-Associated Protein IFITM3 and Modified Variants.Angew Chem Int Ed Engl. 2017 Oct 2;56(41):12639-12643. doi: 10.1002/anie.201707554. Epub 2017 Sep 7.
• [44] Implications of Toll-like receptors in Ebola infection.Expert Opin Ther Targets. 2017 Apr;21(4):415-425. doi: 10.1080/14728222.2017.1299128. Epub 2017 Mar 1.
• [45] Ebola virus VP35has novel NTPase and helicase-like activities.Nucleic Acids Res. 2019 Jun 20;47(11):5837-5851. doi: 10.1093/nar/gkz340.
• [46] Ebola virus encodes a miR-155 analog to regulate importin-5 expression.Cell Mol Life Sci. 2016 Oct;73(19):3733-44. doi: 10.1007/s00018-016-2215-0. Epub 2016 Apr 19.
• [47] Investigating Ebola virus pathogenicity using molecular dynamics.BMC Genomics. 2017 Aug 11;18(Suppl 5):566. doi: 10.1186/s12864-017-3912-2.
• [48] Rapid detection of all known ebolavirus species by reverse transcription-loop-mediated isothermal amplification (RT-LAMP).J Virol Methods. 2017 Aug;246:8-14. doi: 10.1016/j.jviromet.2017.03.011. Epub 2017 Mar 27.
• [49] Emerging targets and novel approaches to Ebola virus prophylaxis and treatment.BioDrugs. 2013 Dec;27(6):565-83. doi: 10.1007/s40259-013-0046-1.
• [50] A Systems Approach Reveals MAVS Signaling in Myeloid Cells as Critical for Resistance to Ebola Virus in Murine Models of Infection.Cell Rep. 2017 Jan 17;18(3):816-829. doi: 10.1016/j.celrep.2016.12.069.
• [51] Functional characterization of Ebola virus L-domains using VSV recombinants.Virology. 2005 Jun 5;336(2):291-8. doi: 10.1016/j.virol.2005.03.027.
• [52] Anti-Niemann Pick C1 Single-Stranded Oligonucleotides with Locked Nucleic Acids Potently Reduce Ebola Virus Infection InVitro.Mol Ther Nucleic Acids. 2019 Jun 7;16:686-697. doi: 10.1016/j.omtn.2019.04.018. Epub 2019 Apr 25.
• [53] Development and evaluation of a fluorogenic 5' nuclease assay to detect and differentiate between Ebola virus subtypes Zaire and Sudan.J Clin Microbiol. 2001 Nov;39(11):4125-30. doi: 10.1128/JCM.39.11.4125-4130.2001.
• [54] Suppression of PACT-induced type I interferon production by herpes simplex virus 1 Us11 protein.J Virol. 2013 Dec;87(24):13141-9. doi: 10.1128/JVI.02564-13. Epub 2013 Sep 25.
• [55] Budding of Ebola Virus Particles Requires the Rab11-Dependent Endocytic Recycling Pathway.J Infect Dis. 2018 Nov 22;218(suppl_5):S388-S396. doi: 10.1093/infdis/jiy460.
• [56] FAM134B, the Selective Autophagy Receptor for Endoplasmic Reticulum Turnover, Inhibits Replication of Ebola Virus Strains Makona and Mayinga.J Infect Dis. 2016 Oct 15;214(suppl 3):S319-S325. doi: 10.1093/infdis/jiw270. Epub 2016 Aug 10.
• [57] Late endosomal transport and tethering are coupled processes controlled by RILP and the cholesterol sensor ORP1L.J Cell Sci. 2013 Aug 1;126(Pt 15):3462-74. doi: 10.1242/jcs.129270. Epub 2013 May 31.
• [58] Functional expression of mouse relaxin and mouse relaxin-3 in the lung from an Ebola virus glycoprotein-pseudotyped lentivirus via tracheal delivery.Endocrinology. 2006 Aug;147(8):3797-808. doi: 10.1210/en.2006-0028. Epub 2006 May 18.
• [59] Identification of RUVBL1 and RUVBL2 as Novel Cellular Interactors of the Ebola Virus Nucleoprotein.Viruses. 2019 Apr 23;11(4):372. doi: 10.3390/v11040372.
• [60] Prevalence of infection among asymptomatic and paucisymptomatic contact persons exposed to Ebola virus in Guinea: a retrospective, cross-sectional observational study.Lancet Infect Dis. 2019 Mar;19(3):308-316. doi: 10.1016/S1473-3099(18)30649-2. Epub 2019 Feb 11.
• [61] Fully Human Immunoglobulin G From Transchromosomic Bovines Treats Nonhuman Primates Infected With Ebola Virus Makona Isolate.J Infect Dis. 2018 Nov 22;218(suppl_5):S636-S648. doi: 10.1093/infdis/jiy377.
• [62] Anti-Siglec-1 antibodies block Ebola viral uptake and decrease cytoplasmic viral entry.Nat Microbiol. 2019 Sep;4(9):1558-1570. doi: 10.1038/s41564-019-0453-2. Epub 2019 Jun 3.
• [63] Staufen1 Interacts with Multiple Components of the Ebola Virus Ribonucleoprotein and Enhances Viral RNA Synthesis.mBio. 2018 Oct 9;9(5):e01771-18. doi: 10.1128/mBio.01771-18.
• [64] TIM-family proteins inhibit HIV-1 release.Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):E3699-707. doi: 10.1073/pnas.1404851111. Epub 2014 Aug 18.
• [65] The Host E3-Ubiquitin Ligase TRIM6 Ubiquitinates the Ebola Virus VP35 Protein and Promotes Virus Replication.J Virol. 2017 Aug 24;91(18):e00833-17. doi: 10.1128/JVI.00833-17. Print 2017 Sep 15.
• [66] A genome-wide CRISPR screen identifies N-acetylglucosamine-1-phosphate transferase as a potential antiviral target for Ebola virus. Nat Commun. 2019 Jan 17;10(1):285.
• [67] Measles-derived vaccines to prevent emerging viral diseases.Microbes Infect. 2018 Oct-Nov;20(9-10):493-500. doi: 10.1016/j.micinf.2018.01.005. Epub 2018 Feb 1.
• [68] Biomechanical characterization of TIM protein-mediated Ebola virus-host cell adhesion.Sci Rep. 2019 Jan 22;9(1):267. doi: 10.1038/s41598-018-36449-2.
• [69] Deception through Mimicry: A Cellular Antiviral Strategy.Cell. 2018 Dec 13;175(7):1728-1729. doi: 10.1016/j.cell.2018.11.033.